Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) continues to surge on the back of positive Phase III trial evaluating Zerenex. After ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE